Trial Profile
A prospective trial evaluating safety and efficacy of bevacizumab plus paclitaxel combination therapy in patients with HER2-negative metastatic breast cancer in routine oncology practice in Germany
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 21 Sep 2020 Results of pooled analysis from four studies (B-SHARE, ML21647, ML21165 and ML22452) presented at the 45th European Society for Medical Oncology Congress.
- 11 Oct 2016 Results (n=2135) of a pooled analysis from ML21165, AVANTI and AVAREG studies assessing real-world effectiveness and safety in clinically important subgroups, presented at the 41st European Society for Medical Oncology Congress.
- 01 Mar 2016 Final results (n=865) published in the Anticancer Research.